Skip to content

An engineered IL-2 partial agonist promotes CD8(+) T cell stemness

  • Date Published

    September 6, 2021

Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, Zhuang X, Mitra S, Lin JX, Gattinoni L, Powell JD, Restifo NP, Garcia KC, Leonard WJ. An engineered IL-2 partial agonist promotes CD8(+) T cell stemness. Nature. 2021 Sep. 597:544-548. doi:10.1038/s41586-021-03861-0. PMID: 34526724